Timing of Initiation of First-line Antiretroviral Therapy

  • Authors: Marshall J. Glesby, MD, PhD; Timothy J. Wilkin, MD, MPH (More Info)
  • Section Editor: Joel E. Gallant, MD, MPH
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Several cohort studies have demonstrated that the risk for certain AIDS- and non-AIDS-related cancers is greater in patients with CD4+ cell counts < 350 cells/mm3[Marin 2009; Guiguet 2009; Monforte 2008; Bruyand 2009]
  • Cancers related to chronic viral infections seem to be particularly associated with immunodeficiency[Silverberg 2009; Grulich 2007]
  • Cumulative HIV viremia may be associated with the risk of non-Hodgkin’s lymphoma and other AIDS-defining cancers, independent of other factors[Zoufaly 2009]

Action required

Keywords: Cardiovascular Disease, Initial Antiretroviral Therapy, Pregnancy, Renal Complications, Special Populations, Viral Hepatitis Coinfection

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.